1. Search Result
Search Result
Results for "

Ovariectomy (OVX)-induced osteoporosis C57BL/6 mice model,

" in MedChemExpress (MCE) Product Catalog:

4603

Inhibitors & Agonists

7

Screening Libraries

34

Fluorescent Dye

124

Biochemical Assay Reagents

363

Peptides

3

MCE Kits

80

Inhibitory Antibodies

559

Natural
Products

114

Isotope-Labeled Compounds

1

Antibodies

33

Click Chemistry

90

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0538

    Xylite

    Autophagy Endogenous Metabolite Bacterial Atg7 Atg8/LC3 Metabolic Disease Cancer
    Xylitol can be classified as a polyol and sugar alcohol, exhibiting inhibitory activity on cancer cell proliferation. It induces autophagy (Autophagy) and cell death in A549 cells by activating the autophagy signaling pathway, as evidenced by the increased expression of LC3-II and Atg5-Atg12 upon Xylitol treatment. Additionally, Xylitol inhibits acetaldehyde production by Candida species, thereby reducing their carcinogenic potential. In vivo, Xylitol induces alterations in the gut microbiota of mice, which may enhance cholesterol accumulation and upregulate hepatic ChREBP, while also slowing tumor growth in the B16F10 melanoma C57BL/6 mouse model .
    Xylitol
  • HY-117427

    Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    D5D-IN-326 is a selective, orally active delta-5 desaturase (D5D) inhibitor, with IC50s of 72 and 22 nM for rat and human D5D in enzymic and cell-based assays, respectively, has no effect on D6D or D9D activity. D5D-IN-326 reduces insulin resistance and decreases body weight in diet-induced obese C57BL/6J mice .
    D5D-IN-326
  • HY-160025

    Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO antagonist-1 (compound 163) is an antagonist of IDO . IDO antagonist-1 inhibits pancreatic adenocarcinoma cells growth in C57BL/6 mice .
    IDO antagonist-1
  • HY-169953

    Pyk2 Metabolic Disease
    BT-Amide is the orally active inhibitor for Pyk2 kinase with IC50 of 44.69 nM. BT-Amide prevents glucocorticoid-induced bone loss, exhibits bone protective activity in C57BL/6 mouse .
    BT-Amide
  • HY-157429

    5-HT Receptor Neurological Disease
    25N-N1-Nap (compound 16) is a β-arrestin-biased 5-HT2A agonist. 25N-N1-Nap antagonizes phencyclidine induced hyperactivity in Male C57BL/6 J mice .
    25N-N1-Nap
  • HY-128435

    Estrogen Receptor/ERR Metabolic Disease
    2,4'-Dihydroxybenzophenone ((Z)-SU4312) exhibited estrogenic activities. 2,4'-Dihydroxybenzophenone has oral bioactivity that can effectively protect C57BL/6J mice from Acetaminophen (HY-66005, APAP)-induced hepatotoxicity .
    2,4'-Dihydroxybenzophenone-1
  • HY-170362

    Cyclic GMP-AMP Synthase Inflammation/Immunology
    cGAS-IN-4 (Compound 36) is an orally active inhibitor for cyclic GMP-AMP synthase (cGAS) with IC50 of 32 nM and 5.8 nM for h-cGAS and m-cGAS. cGAS-IN-4 inhibits the cGAMP in THP-1 cell with an IC50 of 60 nM, which improves the cellular potency. cGAS-IN-4 exhibits anti-inflammatory efficacy in Concanavalin A (HY-P2149)-induced acute liver injury in mouse models . orally active, THP-1, C57Bl/6 mouse, orally active
    cGAS-IN-4
  • HY-144743

    Phosphodiesterase (PDE) Others
    ATX inhibitor 12 (compound 20) is an orally active and potent ATX (autotaxin) inhibitor, with an IC50 of 1.72 nM. ATX inhibitor 12 effectively alleviates lung structural damage with fewer fibrotic lesions at an oral dose of 60 mg/kg in C57Bl/6J mice. ATX inhibitor 12 can be uesd for idiopathic pulmonary fibrosis (IPF) research .
    ATX inhibitor 12
  • HY-168081

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-52 (Compound III-5) is an orally active PD-1/PD-L1 inhibitor that blocks the interaction between PD-1 and PD-L1, with an IC50 of 109.9 nM. PD-1/PD-L1-IN-52 exhibits antitumor activity in a C57BL/6 mouse xenograft model implanted with human PD-1-expressing MC38 colon cancer cells, with a TGI of 49.6% .
    PD-1/PD-L1-IN-52
  • HY-D1056A5

    LPS, from Escherichia coli (K-235)

    Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from E. coli (Escherichia coli) K-235 are lipopolysaccharide endotoxins and TLR-4 activators derived from E. coli, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from E. coli K-235 exhibit a typical three-part structure: O-antigen (O-antigen), core oligosaccharide (core oligosaccharide), and lipid A (Lipid A). Lipopolysaccharides, from E. coli K-235 have a mitogenic effect on C57BL/10ScN spleen cells. Additionally, LPS purified using butanol and deoxycholic acid methods stimulates spleen cells in C57BL/10ScCR and C3H/HeJ mice .
    Lipopolysaccharides, from E. coli K-235
  • HY-158311

    RANKL/RANK p38 MAPK NF-κB Endocrinology
    Anti-osteoporosis agent-8 (Compound 4aa) is an inhibitor for RANKL, which inhibits RANKL-induced osteoclastogenesis and osteoclast differentiation (IC50 is 2.41 μM) in cells RAW264.7. Anti-osteoporosis agent-8 ameliorates bone loss in an ovariectomized (OVX) mice model .
    Anti-osteoporosis agent-8
  • HY-W012980

    Endogenous Metabolite AMPK PKA Metabolic Disease
    Isovaleric acid is an oral active short-chain fatty acid that inhibits osteoclast differentiation by stimulating AMPK phosphorylation and promotes colonic smooth muscle relaxation by activating the cAMP/PKA pathway. Isovaleric acid can be used in research on skeletal diseases (such as osteoporosis) and intestinal disorders .
    Isovaleric acid
  • HY-W012980R

    Endogenous Metabolite AMPK PKA Metabolic Disease
    Isovaleric acid (Standard) is the analytical standard of Isovaleric acid. This product is intended for research and analytical applications. Isovaleric acid is an oral active short-chain fatty acid that inhibits osteoclast differentiation by stimulating AMPK phosphorylation and promotes colonic smooth muscle relaxation by activating the cAMP/PKA pathway. Isovaleric acid can be used in research on skeletal diseases (such as osteoporosis) and intestinal disorders .
    Isovaleric acid (Standard)
  • HY-155985

    Others Metabolic Disease
    Anti-osteoporosis agent-6 (compound 174) is an anti-osteoporosis agent. Anti-osteoporosis agent-6 has 14.11% inhibition rate against osteoclast formation at 10 μM .
    Anti-osteoporosis agent-6
  • HY-169070

    PPAR Others
    Anti-osteoporosis agent-10 is an osteoporosis inhibitor. Anti-osteoporosis agent-10 can suppress the generation of osteoclasts, with an IC50 of 0.042 μM. Anti-osteoporosis agent-10 also has antagonistic activity on PPARγ, with an EC50 value of 0.75 μM .
    Anti-osteoporosis agent-10
  • HY-155977

    Others Others
    Anti-osteoporosis agent-5 (compound 189) is a potent inhibitor of the formation of osteoclasts .
    Anti-osteoporosis agent-5
  • HY-149852

    Others Inflammation/Immunology
    Anti-osteoporosis agent-3 (Compound 11), a PMSA derivative, is an anti-osteoporosis agent. Anti-osteoporosis agent-3 inhibits osteoclastogenesis with an IC50 value of 322.9 nM in vitro. Anti-osteoporosis agent-3 also blocks the formation of F-action belts and bone resorption .
    Anti-osteoporosis agent-3
  • HY-168090

    p38 MAPK NF-κB RANKL/RANK Endocrinology
    Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. Anti-osteoporosis agent-11 has the most significant inhibitory effect on osteoclast differentiation, with an IC50 value of 0.36 μM. In addition, Anti-osteoporosis agent-11 inhibits osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking rankl-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways .
    Anti-osteoporosis agent-11
  • HY-145896

    Apoptosis Inflammation/Immunology
    Anti-osteoporosis agent-1 (comp 4aa) is a potent replication protein A (RPA) inhibitor (IC50=18 µM) .
    Anti-osteoporosis agent-1
  • HY-N11514

    Others Inflammation/Immunology
    Anti-osteoporosis agent-2 (Compound 10) is an anti-osteoporosis agent. Anti-osteoporosis agent-2 inhibits differentiation on osteoclast induced by RANKL .
    Anti-osteoporosis agent-2
  • HY-49069

    Drug Derivative Others
    Anti-osteoporosis agent-7 (Compound 133) is a potential anti-osteoporosis agent showing high inhibition of osteoclast formation.
    Anti-osteoporosis agent-7
  • HY-149472

    NF-κB PI3K Inflammation/Immunology
    Anti-osteoporosis agent-4 (Compound 11h) inhibits differentiation of primary osteoclasts. Anti-osteoporosis agent-4 attenuates RANKL-induced osteoclastogenesis. Anti-osteoporosis agent-4 inhibits osteoclast formation with an IC50 value of 358.29 nM. Anti-osteoporosis agent-4 inhibits PI3K/AKT and IκBα/NF-κB signaling pathway activation .
    Anti-osteoporosis agent-4
  • HY-130237

    Reactive Oxygen Species Metabolic Disease Cancer
    Cinnamtannin B-1 is a proanthocyanidin with multiple biological functions, including antioxidant effects and inhibiting the production of reactive oxygen species (ROS). Cinnamtannin B-1 inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced osteoporosis in vivo. Cinnamtannin B-1 can be used for the research osteoporosis and colon cancers .
    Cinnamtannin B-1
  • HY-164532

    Chloride Channel Metabolic Disease
    NS3736 is an orally effective chloride channel inhibitor that can be used for the research of osteoporosis. NS3736 targets the CIC-7 channel in osteocytes, blocks osteoclast acidification and resorption in vitro, with IC50=30 μM. In a rat model of ovariectomy-induced osteoporosis, NS3736 can enhance bone strength and bone density .
    NS3736
  • HY-130237R

    Reactive Oxygen Species Metabolic Disease Cancer
    Cinnamtannin B-1 (Standard) is the analytical standard of Cinnamtannin B-1. This product is intended for research and analytical applications. Cinnamtannin B-1 is a proanthocyanidin with multiple biological functions, including antioxidant effects and inhibiting the production of reactive oxygen species (ROS). Cinnamtannin B-1 inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced osteoporosis in vivo. Cinnamtannin B-1 can be used for the research osteoporosis and colon cancers .
    Cinnamtannin B-1 (Standard)
  • HY-163847

    MMP Cathepsin Inflammation/Immunology
    Anti-osteoporosis agent-9 (compound 5b) is a N-cyclopropyl-4-((4-((4-(trifluoromethyl)phenyl)sulfonyl)piperazin-1-yl)methyl)benzamide derivative that shows anti-osteoclast activity .
    Anti-osteoporosis agent-9
  • HY-N9331

    Cimicidanol-3-O-β-d-xyloside

    Others Metabolic Disease
    Cimicifugoside H-1, a cyclolanostanol xyloside, is a major constituent of C. foetida L. extract. Cimicifugoside H-1 inhibits bone resorption and ovariectomy-induced bone loss .
    Cimicifugoside H-1
  • HY-B1192
    Estradiol benzoate
    10+ Cited Publications

    β-Estradiol 3-benzoate; 17β-Estradiol 3-benzoate

    Estrogen Receptor/ERR HBV Bcl-2 Family Neurological Disease
    Estradiol benzoate (β-Estradiol 3-benzoate) is a HBx protein inhibitor and inhibits androgen and hepatitis B virus (HBV) transcription, replication. Estradiol benzoate shows antifertility effects, anti- Toxoplasma gondii activity and can improve memory behavior of Ovariectomy (Ovx) female mice .
    Estradiol benzoate
  • HY-171218

    Src Cancer
    CGP062464 is an inhibitor of the tyrosine kinase c-Src (IC50: < 50 nM). CGP062464 can be used for research of osteoporosis and tumor-induced hypercalcemia .
    CGP062464
  • HY-10003
    Alfacalcidol
    4 Publications Verification

    1-hydroxycholecalciferol; 1.alpha.-Hydroxyvitamin D3

    VD/VDR Metabolic Disease
    Alfacalcidol (1-hydroxycholecalciferol) is a vitamin D active metabolites, acts as a non-selective VDR activator medication, and widely be used in the management of osteoporosis .
    Alfacalcidol
  • HY-B1192R

    Estrogen Receptor/ERR HBV Bcl-2 Family Neurological Disease
    Estradiol benzoate (Standard) is the analytical standard of Estradiol benzoate. This product is intended for research and analytical applications. Estradiol benzoate (β-Estradiol 3-benzoate) is a HBx protein inhibitor and inhibits androgen and hepatitis B virus (HBV) transcription, replication. Estradiol benzoate shows antifertility effects, anti- Toxoplasma gondii activity and can improve memory behavior of Ovariectomy (Ovx) female mice .
    Estradiol benzoate (Standard)
  • HY-122359

    L-Centchroman; L-Ormeloxifene

    Estrogen Receptor/ERR Endocrinology Cancer
    Levormeloxifene (L-Centchroman) is a selective estrogen receptor modulator (SERM), which prevents and ameliorates postmenopausal osteoporosis. Levormeloxifene causes multiple adverse gynecological effects .
    Levormeloxifene
  • HY-169332

    Piezo Channel ERK Metabolic Disease
    Piezo1 agonist 1-d2 (Compound 12a) is an agonist for Piezo1 with an EC50 of 2.21 μM. Piezo1 agonist 1-d2 activates the Ca 2+-related ERK signaling pathway, and thus promotes the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). Piezo1 agonist 1-d2 ameliorates disuse osteoporosis in the hindlimb-unloading (HU) rat model .
    Piezo1 agonist 1-d2
  • HY-126426

    DNA Methyltransferase Cardiovascular Disease
    CBHcy is an inhibitor for betaine-homocysteine S-methyltransferase (BGMT), with an IC50 of 0.09 μM. CBHcy upregulates the plasma total homocysteine and causes transient hyperhomocysteinemia in mice model .
    CBHcy
  • HY-10003R

    VD/VDR Metabolic Disease
    Alfacalcidol (Standard) is the analytical standard of Alfacalcidol. This product is intended for research and analytical applications. Alfacalcidol (1-hydroxycholecalciferol) is a vitamin D active metabolites, acts as a non-selective VDR activator medication, and widely be used in the management of osteoporosis .
    Alfacalcidol (Standard)
  • HY-135588

    Drug Metabolite Metabolic Disease
    Raloxifene 6,4'-Bis-β-D-glucuronide (compound IV) is a metabolite of Raloxifene. Raloxifene is a selective estrogen receptor antagonist for the prevention of osteoporosis .
    Raloxifene 6,4'-Bis-β-D-glucuronide
  • HY-A0020S

    VD/VDR Metabolic Disease
    Eldecalcitol-d6 is the deuterium labeled Eldecalcitol. Eldecalcitol is an orally active analogue of active vitamin D used in the treatment of osteoporosis.
    Eldecalcitol-d6
  • HY-108685
    Alendronate sodium
    5+ Cited Publications

    Alendronic acid monosodium salt

    Others Metabolic Disease Cancer
    Alendronate sodium is an orally active nitrogen-containing bisphosphonate. Alendronate sodium potently inhibits bone resorption. Alendronate sodium is used for the research of postmenopausal osteoporosis .
    Alendronate sodium
  • HY-163842

    Cathepsin Inflammation/Immunology
    Cathepsin K inhibitor 7 (compound 7) is a Cathepsin K inhibitor with the pKi of 7.3 aganist CatK. Cathepsin K inhibitor 7 can be used for study of osteoporosis .
    Cathepsin K inhibitor 7
  • HY-P3075

    pTHrP (1-34)

    Thyroid Hormone Receptor Inflammation/Immunology
    pTH-Related Protein (1-34) (human, mouse, rat), a fragment of parathyroid hormone-related protein, is an anabolic agent. pTH-Related Protein (1-34) (human, mouse, rat) can be used for postmenopausal osteoporosis study .
    pTH-Related Protein (1-34) (human,mouse,rat)
  • HY-122077

    Chloride Channel Metabolic Disease
    NS5818 is a potent chloride channel inhibitor. NS5818 inhibits acidification and bone resorption. NS5818 has the potential for the research of osteoporosis .
    NS5818
  • HY-105318

    Androgen Receptor Metabolic Disease Endocrinology
    LGD-2226 is a selective and orally active androgen receptor modulator with an EC50 of 0.2 nM and a Ki of 1.5 nM for human androgen receptor. LGD-2226 shows tissue selectivity in animal models, with reduced effects on prostate compared to muscle. LGD-2226 can be used for muscle wasting, osteoporosis and sexual dysfunction .
    LGD-2226
  • HY-120288

    Cathepsin Infection Metabolic Disease
    AM4299B is an inhibitor for thiol protease. AM4299B inhibits bovine spleen cathepsin B, human kidney cathepsin L and papain with IC50s of 0.7, 0.5 and 20 μM, respectively. AM4299B can be used in research in osteoporosis, and has potential to be used as an antiparasitic agent .
    AM4299B
  • HY-117985

    DA-1229

    Dipeptidyl Peptidase Autophagy Metabolic Disease Inflammation/Immunology
    Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
    Evogliptin
  • HY-110195
    Smurf1-IN-A01
    1 Publications Verification

    A01

    HSP Interleukin Related MyD88 NF-κB Estrogen Receptor/ERR Others Cancer
    Smurf1-IN-A01 is a Smurf1 inhibitor. Smurf1-IN-A01 has anticancer activity and can be used for the research of osteoporosis and age-related macular degeneration .
    Smurf1-IN-A01
  • HY-112569

    Methionine Adenosyltransferase (MAT) NF-κB p38 MAPK Cancer
    MAT2A inhibitor 2 is an inhibitor of methionine adenosine transferase 2A (MAT2A) with oral activity. MAT2A inhibitor 2 can be used in osteoporosis study
    MAT2A inhibitor 2
  • HY-117985B

    DA-1229 tartrate

    Dipeptidyl Peptidase Autophagy Metabolic Disease Inflammation/Immunology
    Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
    Evogliptin tartrate
  • HY-123047

    Progesterone Receptor Androgen Receptor Estrogen Receptor/ERR Endocrinology
    Tibolone is a broad spectrum gonadal steroid agonist with progestagenic, androgenic, and estrogenic activities. Tibolone can be used for postmenopausal osteoporosis research .
    Tibolone
  • HY-162683

    CDK Neurological Disease Cancer
    (S)-PHA533533 is a cyclin-dependent kinase 2 (CDK2) inhibitor. (S)-PHA533533 shows anti-tumor activity and can induce widespread neuronal UBE3A expression in angelman syndrome model mice .
    (S)-PHA533533
  • HY-B0257
    Levonorgestrel
    1 Publications Verification

    D-Norgestrel

    Apoptosis Caspase Bcl-2 Family Survivin Endocrinology Cancer
    Levonorgestrel is an orally active inhibitor of progesterone (HY-N0437). Levonorgestrel has anticancer activity and can induce Apoptosis. Levonorgestrel can be used as a contraceptive and in combination with other medications. Levonorgestrel can be used in the study of osteoporosis and uterine leiomyoma .
    Levonorgestrel

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: